M&A

Global Blood Therapeutics shares spike on buzz about a potential Novo buyout

Shares of Global Blood Therapeutics spiked this morning as Reuters and Bloomberg batted around some new buzz that Novo Nordisk has been kicking the tires, considering a buyout.

Reuters reported that Global Blood Therapeutics $GBT has brought in an investment banker to explore a possible sale, but everything is still up in the air.

Cue the intense Twitter interest.

Global Blood’s lead therapy is for sickle cell disease with a big focus on blood disorders. Novo, meanwhile, has been at work on its hemophilia franchise, though its biggest efforts are for diabetes.

Shares of GBT are up a little more than 20% today, helping swell a market cap of around $1.5 billion. That qualifies this company as a modest-sized takeover target for a company like Novo, which doesn’t do a lot of M&A.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 30,000+ biopharma pros who read Endpoints News by email every day.

Free Subscription

RAPS Convergence 2018

Technical Operations Manager
Molecular Templates Austin, TX
Senior Director, Global Commercial Strategy, Rare Disease
Govig BioPharma/Aeglea BioTherapeutics Austin, TX
Senior Manager, Sales & Client Development
Aldevron Boston or San Francisco
Scientist, Cellular Immunology
Codiak BioSciences Cambridge, MA
Director of Quality Assurance
Aldevron Fargo, ND
Principal Scientist, Immuno-Oncology (Inflammation)
Codiak BioSciences Cambridge, MA

Visit Endpoints Careers ->